Eli Lilly and Novo Nordisk are latest to accept quid pro quo of Most Favored Nation drug pricing and onshoring of pharmaceutical manufacturing in return for tariff exemptions.
The new site adds research capacity and reportedly strengthens the company’s U.S. footprint beyond its existing facility and manufacturing operations in New Jersey.
The project includes digital transformation initiatives and process-innovation technologies to more than double production capacity at the company’s Ansan site.
